BIOGEN HIRLULOG LOWER INCIDENCE OF BLEEDING COMPLICATIONS v. HEPARIN IS DEEMED INSUFFICIENT CLINICAL RESULT; FIRM REDEPLOYING RESOURCES TO BETA INTERFERON